2025
Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma.
Amer A, Ansari S, Krayyem A, Kundu S, Khose S, Pokhylevych H, Calle S, Patel C, Yang Z, Liu H, Johnson J. Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma. Journal Of Computer Assisted Tomography 2025 PMID: 39876523, DOI: 10.1097/rct.0000000000001716.Peer-Reviewed Original ResearchHigh-grade gliomasBlood-brain barrierDCE-MRIPeak contrast enhancementQuantify BBB permeabilityTreatment-related changesFollow-up subjectsKtrans mapsTrue progressionTumor progressionClinical dataConventional MRIPseudoprogressionBBB permeabilityCombined pathologyKtransContrast enhancementT1 enhancementStandard processing methodologyStatistically significant resultsClinical data setsPathologyPatientsGliomaSSS technique
2024
Divergent brain solute clearance in rat models of cerebral amyloid angiopathy and Alzheimer’s disease
Koundal S, Chen X, Gursky Z, Lee H, Xu K, Liang F, Xie Z, Xu F, Lin H, Van Nostrand W, Gu X, Elkin R, Tannenbaum A, Benveniste H. Divergent brain solute clearance in rat models of cerebral amyloid angiopathy and Alzheimer’s disease. IScience 2024, 27: 111463. PMID: 39720539, PMCID: PMC11667077, DOI: 10.1016/j.isci.2024.111463.Peer-Reviewed Original Research
2020
Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI
Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. European Radiology 2020, 31: 2737-2746. PMID: 33123796, PMCID: PMC8043967, DOI: 10.1007/s00330-020-07381-9.Peer-Reviewed Original ResearchConceptsTumor response criteriaOverall survivalAdvanced-stage HCCDisease progressionSorafenib therapyDisease controlResponse criteriaCox proportional hazards regression modelAdvanced-stage hepatocellular carcinomaProportional hazards regression modelsDCE-MRIInitiation of sorafenibTumor response analysisMultivariable Cox regressionIndependent risk factorMethodsThis retrospective analysisIndependent prognostic factorInitiation of treatmentKaplan-Meier analysisKaplan-Meier curvesHazards regression modelsLog-rank testStratification of patientsTotal tumor volumeArterial phase MRI
2017
Dynamic contrast‐enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases
Hatzoglou V, Tisnado J, Mehta A, Peck KK, Daras M, Omuro AM, Beal K, Holodny AI. Dynamic contrast‐enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases. Cancer Medicine 2017, 6: 761-767. PMID: 28303695, PMCID: PMC5387174, DOI: 10.1002/cam4.1046.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesNSCLC brain metastasesLung cancer brain metastasesBrain metastasesCancer brain metastasesCell lung cancer brain metastasesDCE-MRIPrimary brain tumorsDifferent primary sitesImportant clinical implicationsMann-Whitney U testVolume transfer coefficientTumor histologyMultiple malignanciesMRI perfusionBrain tumorsMetastasisPrimary siteConventional MRIClinical implicationsPerfusion parametersTumor microvasculatureROC analysisU testPlasma volume
2016
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer
Wong A, Sundar R, Wang T, Ng T, Zhang B, Tan S, Soh T, Pang A, Tan C, Ow S, Wang L, Mogro J, Ho J, Jeyasekharan A, Huang Y, Thng C, Chan C, Hartman M, Iau P, Buhari S, Goh B, Lee S. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget 2016, 7: 64089-64099. PMID: 27577069, PMCID: PMC5325427, DOI: 10.18632/oncotarget.11596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnthracyclinesAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsContrast MediaCyclophosphamideDisease-Free SurvivalDoxorubicinDrug Administration ScheduleFemaleHumansImmunohistochemistryIndolesMagnetic Resonance ImagingMiddle AgedNeoadjuvant TherapyPreoperative PeriodPyrrolesSunitinibTreatment OutcomeConceptsPathological complete responseVascular normalization indexChemotherapy dose delaysLow-doseDose delaysDCE-MRIPhase IbDecreased lymphatic vessel densityIntra-tumoral drug deliveryPathologic complete response rateRecommended phase II dosePhase II doseDose of sunitinibTreatment of breast cancerDCE-MRI parametersPre-operative treatmentAnthracycline-based chemotherapyOpen-label studyRandomized to chemotherapyTumor vessel normalizationLymphatic vessel densityEnhance chemotherapy efficacyBreast cancer patientsFunctional imaging biomarkersPharmacodynamic evidenceDynamic contrast-enhanced MRI detects acute radiotherapy-induced alterations in mandibular microvasculature: prospective assessment of imaging biomarkers of normal tissue injury
Sandulache V, Hobbs B, Mohamed A, Frank S, Song J, Ding Y, Ger R, Court L, Kalpathy-Cramer J, Hazle J, Wang J, Awan M, Rosenthal D, Garden A, Gunn G, Colen R, Elshafeey N, Elbanan M, Hutcheson K, Lewin J, Chambers M, Hofstede T, Weber R, Lai S, Fuller C. Dynamic contrast-enhanced MRI detects acute radiotherapy-induced alterations in mandibular microvasculature: prospective assessment of imaging biomarkers of normal tissue injury. Scientific Reports 2016, 6: 29864. PMID: 27499209, PMCID: PMC4976364, DOI: 10.1038/srep29864.Peer-Reviewed Original ResearchConceptsDCE-MRIBone vascularizationHead and neck tumorsHead and neck cancerProspective imaging trialExternal beam radiotherapyDynamic contrast-enhanced MRINormal tissue injuryNormal tissue toxicityDCE-MRI scansContrast-enhanced MRIDetect dose-dependent changesDose-dependent alterationsDose-dependent changesMulti-parametric MRIBeam radiotherapyNeck tumorsTissue toxicityNeck cancerInstitutional experienceVascular injuryTissue injuryImaging trialsKtransImaging modalities
2015
A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation
Hatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, Schneider T, Woo KM, Zhang Z, Peck KK, Beal K, Young RJ. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro-Oncology 2015, 18: 873-880. PMID: 26688076, PMCID: PMC4864262, DOI: 10.1093/neuonc/nov301.Peer-Reviewed Original ResearchConceptsRadiation injuryPET-CTRadiation therapyProspective trialDCE-MRITumor progressionMaximum standardized uptake valueFluorine-18 fluorodeoxyglucose PET-CTFDG PET-CTDiagnosis of progressionNormal brain ratioFluorodeoxyglucose PET-CTStandardized uptake valueDynamic contrast-enhanced MRIWilcoxon rank sum testContrast-enhanced MRIBrain tumor progressionEffective imaging techniqueVolume transfer coefficientRank sum testCranial irradiationBrain ratioBrain malignanciesLesion outcomeBrain lesionsClinical evaluation of contrast-enhanced digital mammography and contrast enhanced tomosynthesis—Comparison to contrast-enhanced breast MRI
Chou C, Lewin J, Chiang C, Hung B, Yang T, Huang J, Liao J, Pan H. Clinical evaluation of contrast-enhanced digital mammography and contrast enhanced tomosynthesis—Comparison to contrast-enhanced breast MRI. European Journal Of Radiology 2015, 84: 2501-2508. PMID: 26456307, DOI: 10.1016/j.ejrad.2015.09.019.Peer-Reviewed Original ResearchConceptsContrast-enhanced digital mammographyDCE-MRIBreast MRIDigital mammographyBI-RADSNon-target breastInstitutional review board approvalBI-RADS 4Contrast-enhanced breast MRIReview board approvalConventional digital mammographyBI-RADS categoryCranio-caudal viewContrast agent injectionAbnormal mammographyBenign lesionsMalignant lesionsNo significant differenceBoard approvalDiagnostic accuracyMediolateral-oblique viewClinical evaluationDynamic contrastAgent injectionLesions
2014
NI-57DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE PERFUSION WEIGHTED IMAGING (DCE-MRI) AND DIFFUSION WEIGHTED IMAGING (DWI) FOR PHARMACODYNAMIC EVALUATION OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) AND TEMOZOLOMIDE IN MALIGNANT GLIOMA
Magge R, Perez J, Young R, Kaley T, Pentsova E, DeAngelis L, Diamond E, Mellinghoff I, Peck K, Anderson B, Gorman G, Mclean S, Karmali R, Omuro A. NI-57DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE PERFUSION WEIGHTED IMAGING (DCE-MRI) AND DIFFUSION WEIGHTED IMAGING (DWI) FOR PHARMACODYNAMIC EVALUATION OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) AND TEMOZOLOMIDE IN MALIGNANT GLIOMA. Neuro-Oncology 2014, 16: v150-v151. PMCID: PMC4218384, DOI: 10.1093/neuonc/nou264.55.Peer-Reviewed Original ResearchBlood perfusionMalignant gliomasVascular permeabilityDCE-MRIProgressive malignant gliomaPhase I trialSubset of patientsContrast-Enhanced Magnetic ResonanceWnt/b-cateninMann-Whitney U testEarly pharmacodynamic effectsVolumetric histogram analysisMechanism of actionBiological effectsAdvanced imaging techniquesI trialOral inhibitorEarly drug developmentPharmacodynamic effectsVascular permeability parametersDrug exposurePharmacodynamic evaluationVEGF blockadeAdvanced neuroimagingBrain tumorsRegional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials
Konstantinidis I, Do R, Gultekin D, Gönen M, Schwartz L, Fong Y, Allen P, D’Angelica M, DeMatteo R, Klimstra D, Kemeny N, Jarnagin W. Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials. Annals Of Surgical Oncology 2014, 21: 2675-2683. PMID: 24664624, PMCID: PMC4516216, DOI: 10.1245/s10434-014-3649-y.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBile Duct NeoplasmsBile Ducts, IntrahepaticBiomarkers, TumorCholangiocarcinomaDexamethasoneFemaleFloxuridineFollow-Up StudiesHumansInfusions, Intra-ArterialMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingPrognosisProspective StudiesRetrospective StudiesSurvival RateConceptsUnresectable intrahepatic cholangiocarcinomaHepatic arterial infusionIntrahepatic cholangiocarcinomaDCE-MRIMagnetic resonance imagingMedian hepatic progression-free survivalClinical trialsHepatic progression-free survivalContrast-enhanced magnetic resonance imagingDynamic contrast-enhanced magnetic resonance imagingProgression-free survivalResponse Evaluation CriteriaAdvanced intrahepatic cholangiocarcinomaResonance imagingDied of diseaseResultsForty-four patientsProspective clinical trialPre-treatment DCE-MRILong-term outcomesDynamic magnetic resonance imagingSurvival updateStable diseasePartial responseMedian survivalRegional chemotherapy
2013
Hepatic arterial infusion for unresectable intrahepatic cholangiocarcinoma: An update on survival from two prospective clinical trials.
Konstantinidis I, Do R, Gultekin D, Gonen M, Schwartz L, Fong Y, Allen P, D'Angelica M, DeMatteo R, Klimstra D, Kemeny N, Jarnagin W. Hepatic arterial infusion for unresectable intrahepatic cholangiocarcinoma: An update on survival from two prospective clinical trials. Journal Of Clinical Oncology 2013, 31: 4116-4116. DOI: 10.1200/jco.2013.31.15_suppl.4116.Peer-Reviewed Original ResearchHepatic arterial infusionUnresectable intrahepatic cholangiocarcinomaPre-treatment DCE-MRIIntrahepatic cholangiocarcinomaDCE-MRIArterial infusionClinical trialsHepatic arterial infusion chemotherapyAdvanced intrahepatic cholangiocarcinomaDied of diseaseLong-term outcomesStable diseasePartial responseMedian survivalTumor perfusionProlonged survivalTumor perfusion dataPoor survivalFollow-upPatientsDynamic contrastLiver progressionPerfusion dataSurvival dataSurvival
2012
Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors.
Borad M, Ramanathan R, Bessudo A, LoRusso P, Shepard H, Maneval D, Jiang P, Zhu J, Frost G, Infante J. Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors. Journal Of Clinical Oncology 2012, 30: 2579-2579. DOI: 10.1200/jco.2012.30.15_suppl.2579.Peer-Reviewed Original ResearchMusculoskeletal eventsSolid tumorsFDG-PETDCE-MRITumor biopsiesTumor perfusionInterstitial fluid pressureOngoing phase 1 studiesTreatment-refractory solid tumorsWeekly dosing scheduleDose limiting toxicitiesPhase 1 studyWeeks of dosingEfficacy of chemotherapyTerminal half lifeFDG-PET imagesOral dexamethasoneTumor hyaluronanCytotoxic chemotherapyMost patientsDosing schedulesLimiting toxicitiesPoor prognosisSystemic exposureHA depletion
2007
First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors
Rosen L, Hong D, Chap L, Kurzrock R, Garcia A, Rasmussen E, Nguyen L, Hwang Y, Storgard C, Herbst R. First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors. Journal Of Clinical Oncology 2007, 25: 3522-3522. DOI: 10.1200/jco.2007.25.18_suppl.3522.Peer-Reviewed Original ResearchAMG 386Advanced solid tumorsAdverse eventsStable diseaseTumor responseHuman studiesGrade 2Solid tumorsDCE-MRIMinor clinical responseSignificant vascular effectsSerum CA 125Treatment-related toxicityDose-limiting toxicityFurther clinical studiesEvaluable patientsEvaluable subjectsPeripheral edemaRECIST criteriaAdult patientsClinical responseProgressive diseaseWeekly administrationVascular effectsCA 125
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply